There was a dose-response pattern of psychological distress associated with significantly increased risk for COPD, cardiovascular disease, and arthritis.
Jennifer DiSanto
Advertisement
Articles by Jennifer DiSanto
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Rheumatology Live
1
Sonelokimab Reduces Inflammation, Osteoblastic Activity in Phase 2 Proof-of-Concept axSpA Study
2
Bimekizumab Beats Risankizumab on ACR50 in First IL-17A/F vs IL-23 Head-to-Head
3
OLINGUITO: Filgotinib Meets Phase 3 Primary Endpoint in r/nr-axSpA, With Xenofon Baraliakos, MD, PhD
4
Nipocalimab Demonstrates Proof of Concept for FcRn Blockade for SLE
5